Depósito Digital de Documentos de la UAB Encontrados 11 registros  1 - 10siguiente  ir al registro: La búsqueda tardó 0.01 segundos. 
1.
8 p, 196.5 KB Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer / Sclafani, Francesco (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Brown, Gina (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Cunningham, David (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Wotherspoon, Andrew (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ; Mendes, Larissa Sena Teixeira (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ; Balyasnikova, Svetlana (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Evans, Jessica (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Peckitt, Clare (Clinical Research & Development, The Royal Marsden NHS Foundation Trust) ; Begum, Ruwaida (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Tait, Diana (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Glimelius, Bengt (Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, University of Uppsala) ; Roselló, Susana (Department of Haematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia) ; Thomas, Janet (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Oates, Jacqui (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Chau, Ian (Department of Medicine, The Royal Marsden NHS Foundation Trust)
Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). [...]
2017 - 10.1038/bjc.2017.320
British Journal of Cancer, Vol. 117 (09 2017) , p. 1478-1485  
2.
12 p, 1.7 MB Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma : the oncogenic role of the ligands / Almazán-Moga, A (Hospital Universitari Vall d'Hebron) ; Zarzosa, P (Hospital Universitari Vall d'Hebron) ; Molist, C (Hospital Universitari Vall d'Hebron) ; Velasco, Pablo (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública) ; Pyczek, J (Institute of Human Genetics, University of Goettingen) ; Simon-Keller, K (Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg) ; Giralt, I (Hospital Universitari Vall d'Hebron) ; Vidal, I (LHospital Universitari Vall d'Hebron) ; Navarro, N (Hospital Universitari Vall d'Hebron) ; Segura, M F (Hospital Universitari Vall d'Hebron) ; Soriano, A (Hospital Universitari Vall d'Hebron) ; Navarro, S (Universitat de València. Departament de Patologia) ; Tirado, O M (Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)) ; Ferreres, J C (Hospital Universitari Vall d'Hebron) ; Santamaria, A (Hospital Universitari Vall d'Hebron) ; Rota, R (Ospedale Pediatrico Bambino Gesù, IRCCS) ; Hahn, H (Institute of Human Genetics, University of Goettingen) ; Sánchez de Toledo, J (Hospital Universitari Vall d'Hebron) ; Roma, J (Hospital Universitari Vall d'Hebron) ; Gallego, S (Hospital Universitari Vall d'Hebron)
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children. The Hedgehog (HH) pathway is known to develop an oncogenic role in RMS. However, the molecular mechanism that drives activation of the pathway in RMS is not well understood. [...]
2017 - 10.1038/bjc.2017.305
British Journal of Cancer, Vol. 117 (09 2017) , p. 1314-1325  
3.
10 p, 1.9 MB Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer / Codony Servat, Jordi (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Cuatrecasas Freixas, Miriam ; Asensio, Elena (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Montironi, Carla (Hospital Clínic) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Marín Aguilera, Mercedes (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Horndler, Carlos (Hospital Miguel Servet) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Rubini, Michele (Department of Experimental and Diagnostic Medicine, University of Ferrara) ; Jares, Pedro (Hospital Clínic) ; Reig, Oscar (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Victoria, Iván (Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Universitat de Barcelona) ; Gaba, Lydia (Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Universitat de Barcelona) ; Martín Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ; Alonso, Vicente (Hospital Miguel Servet) ; Escudero, Pilar (Hospital Clínico Universitatio Lozano Blesa) ; Fernández-Martos, Carlos (Instituto Valenciano de Oncología) ; Feliu, Jaime (Hospital La Paz, CIBERONC) ; Méndez, Jose Carlos (Centro Oncológico de Galicia) ; Méndez, Miguel (Hospital de Móstoles) ; Gallego, Javier (Hospital de Elche) ; Salud, Antonieta (Hospital Arnau de Vilanova) ; Rojo, Federico (Pathology Department, Fundación Jiménez Diaz University) ; Castells, Antoni (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Prat, Aleix (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; García-Albéniz, Xabier (Harvard T.H. Chan School of Public Health) ; Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ; Maurel, Joan (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS))
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. [...]
2017 - 10.1038/bjc.2017.279
British Journal of Cancer, Vol. 117 (november 2017) , p. 1777-1786  
4.
9 p, 1.1 MB Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab / Fuchs, Charles S (Dana-Farber Cancer Institute. Harvard Medical School) ; Tabernero Caturla, Josep (Institut d'Oncologia de la Vall Hebron (VHIO)) ; Tomášek, Jiří (Masaryk University. Masaryk Memorial Cancer Institute (Czech Republic)) ; Chau, Ian (Royal Marsden Hospital (United Kingdom)) ; Melichar, Bohuslav (Univerzity Palackeho a Fakultni nemocnice. Onkologicka klinika (Czech Republic)) ; Safran, Howard (Brown University Oncology Research Group (USA)) ; Tehfe, Mustapha A (Centre Hospitalier de Montréal (Canada)) ; Filip, Dumitru (Spitalul Judetean de Urgenta (Romania)) ; Topuzov, Eldar (Northwest State Medical University na II Mechnikov. State Budgetary Educational Institution of Higher Professional Education (SBEIHPE). Ministry of Healthcare of the Russian Federation) ; Schlittler, Luis (Hospital da Cida de Passo Fundo (Brasil)) ; Udrea, Anghel Adrian (Medisprof SRL (Romania)) ; Campbell, William (Hospital Herrera Llerandi (Guatemala)) ; Brincat, Stephen (Sir Anthony Mamo Oncology Centre (Malta)) ; Emig, Michael (Lilly Deutschland GmbH (Germany)) ; Melemed, Symantha A (Eli Lilly and Company. Lilly Corporate Center (USA)) ; Hozak, Rebecca R (Eli Lilly and Company. Lilly Corporate Center (USA)) ; Ferry, David (Eli Lilly and Company (USA)) ; Caldwell, C William (Eli Lilly and Company. Lilly Corporate Center (USA)) ; Ajani, Jaffer A (The University of Texas MD Anderson Cancer Center (USA)) ; Universitat Autònoma de Barcelona
Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. [...]
2016 - 10.1038/bjc.2016.293
British Journal of Cancer, Vol. 115, Issue 8 (October 2016) , p. 974-982  
5.
9 p, 306.4 KB Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer / Élez Fernández, Mª Elena (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Hendlisz, A. (Institut Jules Bordet (Belgium)) ; Delaunoit, T. (Centres Hospitaliers Jolimont (Belgium)) ; Sastre, J. (Hospital Universitario San Carlos) ; Cervantes, A. (Universitat de València. INCLIVA Institut d'Investigació Sanitària) ; Varea, R. (Eli Lilly and Company (Spain)) ; Chao, G. (Eli Lilly and Company (USA)) ; Wallin, J. (Eli Lilly and Company (Suècia)) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Universitat Autònoma de Barcelona
This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC). [...]
2016 - 10.1038/bjc.2015.480
British Journal of Cancer, Vol. 114 (February 2016) , p. 372-380  
6.
8 p, 207.5 KB Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer / Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Cervantes, A (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Roselló, S (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Van Cutsem, E (University Hospitals Gasthuisberg and KU Leuven) ; Tejpar, S (University Hospitals Gasthuisberg and KU Leuven) ; Prenen, H (University Hospitals Gasthuisberg and KU Leuven) ; Martinelli, E (Second University of Naples. Department of Experimental and Clinical Medicine) ; Troiani, T (Second University of Naples. Department of Experimental and Clinical Medicine) ; Laffranchi, B (Merck Serono SA) ; Jego, V (Merck Serono SA) ; von Richter, O (Merck KGaA) ; Ciardiello, F (Second University of Naples. Department of Experimental and Clinical Medicine) ; Universitat Autònoma de Barcelona
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. [...]
2015 - 10.1038/bjc.2015.144
British Journal of Cancer, Vol. 112 (June 2015) , p. 1874-1881  
7.
10 p, 426.6 KB A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies / Spreafico, A. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Delord, J. P. (Institut Claudius Regaud (France)) ; Mattos Arruda, Leticia de (Hospital Universitari Vall d'Hebron) ; Berge, Y. (Institut Claudius Regaud (France)) ; Pérez Rodon, Jordi (Hospital Universitari Vall d'Hebron) ; Cottura, E. (Institut Claudius Regaud (France)) ; Bedard, P. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Akimov, M. (Novartis Pharma AG (Switzerland)) ; Lu, H. (Novartis Pharmaceuticals Corp (USA)) ; Pain, S. (Novartis Pharmaceuticals Corp (USA)) ; Kaag, A. (Novartis Pharma AG (Switzerland)) ; Siu, L. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Cortés Castán, Javier (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Heat-shock protein 990 (HSP990) is a potent and selective synthetic small-molecule HSP90 inhibitor. The primary objectives of this phase I first-in-human study were to determine dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). [...]
2015 - 10.1038/bjc.2014.653
British Journal of Cancer, Vol. 112 (February 2015) , p. 650-659  
8.
9 p, 234.9 KB Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer : results from the GEICAM/2006-14 trial / Alba, E (Hospital Universitario Virgen de la Victoria) ; Albanell, J (Hospital Parc de Salut Mar) ; de la Haba, J (Hospital Universitario Reina Sofía) ; Barnadas, Agustí (Institut d'Investigació Biomèdica Sant Pau) ; Calvo, L (Complejo Hospitalario Universitario de A Coruña) ; Sánchez-Rovira, P (Hospital General de Jaén) ; Ramos, M (Centro Oncológico de Galicia) ; Rojo, F (Fundación Jiménez Díaz) ; Burgués, O (Hospital Clínico Universitario de Valencia) ; Carrasco, E (Grupo GEICAM de Investigación en Cáncer de Mama) ; Caballero, R (Grupo GEICAM de Investigación en Cáncer de Mama) ; Porras, I (Hospital Universitario Reina Sofía) ; Tibau, A (Institut d'Investigació Biomèdica Sant Pau) ; Cámara, M C (Grupo GEICAM de Investigación en Cáncer de Mama) ; Lluch, A (Hospital Clínico Universitario de Valencia) ; Universitat Autònoma de Barcelona. Departament de Medicina
The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. [...]
2014 - 10.1038/bjc.2013.831
British Journal of Cancer, Vol. 110 (01 2014) , p. 1139-1147  
9.
10 p, 579.1 KB Development of robust discriminant equations for assessing subtypes of glioblastoma biopsies / Castells, Xavier (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia molecular) ; Acebes, Juan José (Hospital Universitari de Bellvitge. Institut d'Investigació Biomèdica) ; Majós, Carles (Hospital Universitari de Bellvitge. Institut de Diagnòstic per la Imatge) ; Boluda, Susana (Hospital Universitari de Bellvitge. Institut de Neuropatologia, Institut d'Investigació Biomèdica) ; Julià-Sapé, Margarida (Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Candiota Silveira, Ana Paula (Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Ariño Carmona, Joaquín (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia molecular) ; Barceló, Antonia (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia molecular) ; Arús i Caraltó, Carles (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular. Grup d'Aplicacions Biomèdiques de la RMN (GABRMN))
In the preceding decade, various studies on glioblastoma (Gb) demonstrated that signatures obtained from gene expression microarrays correlate better with survival than with histopathological classification. [...]
2012 - 10.1038/bjc.2012.174
British journal of cancer, Vol. 106, número 11 (May 2012) , p. 1816-1825  
10.
7 p, 393.3 KB Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas / Gallardo, A (Institut d'Investigació Biomèdica Sant Pau) ; Lerma, E (Institut d'Investigació Biomèdica Sant Pau) ; Escuin, D (Institut d'Investigació Biomèdica Sant Pau) ; Tibau, A (Institut d'Investigació Biomèdica Sant Pau) ; Muñoz, J (Institut d'Investigació Biomèdica Sant Pau) ; Ojeda, B (Institut d'Investigació Biomèdica Sant Pau) ; Barnadas, Agustí (Institut d'Investigació Biomèdica Sant Pau) ; Adrover, E (Hospital General Universitario de Alicante. Departamento de Oncología Clínica) ; Sánchez-Tejada, L (Hospital General Universitario de Alicante) ; Giner, D (Hospital General Universitario de Alicante) ; Ortiz-Martínez, F (Hospital General Universitario de Alicante) ; Peiró, G (Hospital General Universitario de Alicante) ; Universitat Autònoma de Barcelona
Trastuzumab resistance hampers its well-known efficacy to control HER2-positive breast cancer. The involvement of PI3K/Akt pathway in this mechanism is still not definitively confirmed. We selected 155 patients treated with trastuzumab after development of metastasis or as adjuvant/neoadjuvant therapy. [...]
2012 - 10.1038/bjc.2012.85
British Journal of Cancer, Vol. 106 (03 2012) , p. 1367-1373  

Depósito Digital de Documentos de la UAB : Encontrados 11 registros   1 - 10siguiente  ir al registro:
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.